Hospitalizations related to alcohol use disorder (AUD) are common. Yet, few patients receive pharmacotherapy consistent with guideline recommendations. Previous concerns over the potential hepatotoxicity of naltrexone have been disproven and recent studies have shown its safety and efficacy in patients with cirrhosis. Naltrexone is an effective therapy to reduce heavy alcohol consumption, however, lack of knowledge among prescribers inhibits greater uptake. Hospitalization is an opportune time for change-naltrexone can promote the reduction or cessation of unhealthy alcohol consumption, as well as subsequent readmissions or progression of alcohol-related liver disease. Hospitalists should stop avoiding naltrexone in the treatment of AUD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jhm.13569 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fibromyalgia: do I tackle you with pharmacological treatments?
Pain Rep
February 2025
Pain Department, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, INSERM U987, Paris, France.
Pharmacological approaches are frequently proposed in fibromyalgia, based on different rationale. Some treatments are proposed to alleviate symptoms, mainly pain, fatigue, and sleep disorder. Other treatments are proposed according to pathophysiological mechanisms, especially central sensitization and abnormal pain modulation.
View Article and Find Full Text PDFThings We Do for No Reason™: Avoiding naltrexone for alcohol use disorder in liver disease.
J Hosp Med
December 2024
Division of Hospital Medicine and Division of General Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Hospitalizations related to alcohol use disorder (AUD) are common. Yet, few patients receive pharmacotherapy consistent with guideline recommendations. Previous concerns over the potential hepatotoxicity of naltrexone have been disproven and recent studies have shown its safety and efficacy in patients with cirrhosis.
View Article and Find Full Text PDFThe Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research.
CNS Drugs
January 2025
School of Population and Global Health, University of Western Australia, Nedlands, WA, 6009, Australia.
Article Synopsis
- - The study reviews the safety concerns of various alcohol pharmacotherapies during pregnancy, as current options for pregnant individuals with alcohol use disorders (AUD) are limited due to unknown teratogenic risks.
- - A total of 105 studies were analyzed, focusing on medications like naltrexone, acamprosate, disulfiram, and topiramate, with findings suggesting that naltrexone might be safer than other options for opioid use disorders, despite being less studied for AUD specifically.
- - The review highlights significant safety concerns, noting disulfiram and topiramate's links to congenital anomalies, while acamprosate showed potential neuroprotective benefits without clear adverse effects, creating a complex picture of risks and benefits
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.
CNS Drugs
September 2024
Lindner Center of HOPE, Mason, OH, USA.
Binge eating disorder (BED) is the most common specific eating disorder (ED). It is frequently associated with attention deficit hyperactivity disorder (ADHD), depression, bipolar disorder (BD), anxiety disorders, alcohol and nicotine use disorder, and obesity. The aim of this narrative review was to summarize the evidence for the pharmacological treatment of BED and its comorbid disorders.
View Article and Find Full Text PDFMultimodal Acute Pain Management in the Parturient with Opioid Use Disorder: A Review.
J Pain Res
February 2024
Department of Anesthesiology, Westchester Medical Center/New York Medical College, Valhalla, NY, USA.
The opioid epidemic in the United States has led to an increasing number of pregnant patients with opioid use disorder (OUD) presenting to obstetric units. Caring for this complex patient population requires an interdisciplinary approach involving obstetricians, anesthesiologists, addiction medicine physicians, psychiatrists, and social workers. The management of acute pain in the parturient with OUD can be challenging due to several factors, including respiratory depression, opioid tolerance, and opioid-induced hyperalgesia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!